PBE

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-206.3K ExitQ4 2025 $206k -- $89.34
Ken GriffinCitadel Advisors $-568.9K ExitQ1 2025 $569k -- $89.34

News

zacks.comIs Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?zacks.comJun 12

zacks.comShould You Invest in the Invesco Biotechnology & Genome ETF (PBE)?zacks.comJun 10

zacks.comIs Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?zacks.comApr 9

zacks.comShould You Invest in the Invesco Biotechnology & Genome ETF (PBE)?zacks.comApr 7

Trade PBE

About Invesco Biotechnology & Genome ETF

The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.

IPO Date: Jun 23, 2005

Market Data

Open: $84.64
High: $84.89
Low: $83.55
Volume: 4.8K
Avg Volume: 5.6K
52W High: $85.73
52W Low: $62.63

Valuation

Market Cap: $257.8M
Dividend Yield: 86.7%

Financials

Financial statement snapshot is not available yet.

Events

DividendMar 23

$0.08244